{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:56:02Z","timestamp":1780368962173,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","academicradiology.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.acra.2024.06.034","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:55:45Z","timestamp":1721177745000},"page":"5008-5021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prediction of Prognosis and Response to Androgen Deprivation Therapy in Intermediate to High-Risk Prostate Cancer Using 18F-FDG PET\/CT Radiomics"],"prefix":"10.1016","volume":"31","author":[{"given":"Jianyi","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.acra.2024.06.034_bib2","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"issue":"49","key":"10.1016\/j.acra.2024.06.034_bib3","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.acra.2024.06.034_bib5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijrobp.2020.12.032","article-title":"Comparative effectiveness research in localized prostate cancer: a 10-year follow-up cohort study","volume":"110","author":"Garin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.acra.2024.06.034_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/cancers10100379","article-title":"Identification of the transcription factor relationships associated with androgen deprivation therapy response and metastatic progression in prostate cancer","volume":"10","author":"Sharma","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.acra.2024.06.034_bib7","unstructured":"Mettlin C., Littrup Pj Fau - Kane R.A., Kane Ra Fau - Murphy G.P., et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. (0008\u2013543X (Print))."},{"issue":"3","key":"10.1016\/j.acra.2024.06.034_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3322\/caac.21391","article-title":"Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib9","first-page":"47","article-title":"A systematic review on the role of imaging in early recurrent prostate cancer","volume":"2","author":"De Visschere","year":"2019","journal-title":"Eur\u00a0Urol\u00a0Oncol"},{"issue":"19","key":"10.1016\/j.acra.2024.06.034_bib10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.acra.2024.06.034_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/RLU.0b013e318252d829","article-title":"Prospective evaluation of 18F-NaF and 18F-FDG PET\/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer","volume":"37","author":"Jadvar","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12149-012-0660-x","article-title":"The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey","volume":"27","author":"Minamimoto","year":"2013","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.acra.2024.06.034_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41391-020-0202-x","article-title":"GLUT1 expression in high-risk prostate cancer: correlation with (18)F-FDG-PET\/CT and clinical outcome","volume":"23","author":"Meziou","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.acra.2024.06.034_bib14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.euf.2018.03.008","volume":"5","author":"Lavallee","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.acra.2024.06.034_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2967\/jnumed.118.222893","article-title":"Introduction to radiomics","volume":"61","author":"Mayerhoefer","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2024.06.034_bib16","unstructured":"Gillies R.J., Kinahan P.E., Hricak H.. Radiomics: Images Are More than Pictures, They Are Data. (1527\u20131315 (Electronic))."},{"issue":"6","key":"10.1016\/j.acra.2024.06.034_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11547-018-0966-4","article-title":"Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer","volume":"124","author":"Abdollahi","year":"2019","journal-title":"Radiol Med"},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.21037\/qims.2019.12.06","article-title":"Radiomics prediction model for the improved diagnosis of clinically significant prostate cancer on biparametric MRI","volume":"10","author":"Li","year":"2020","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.acra.2024.06.034_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fonc.2020.00888","article-title":"Development of a novel, multi-parametric, MRI-based radiomic nomogram for differentiating between clinically significant and insignificant prostate cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.acra.2024.06.034_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00066-021-01886-y","article-title":"Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy","volume":"198","author":"Franzese","year":"2022","journal-title":"Strahlenther Onkol"},{"issue":"16","key":"10.1016\/j.acra.2024.06.034_bib21","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.3390\/cancers15164163","article-title":"Prostate region-wise imaging biomarker profiles for risk stratification and biochemical recurrence prediction","volume":"15","author":"Sanchez Iglesias","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.acra.2024.06.034_bib22","unstructured":"Ghezzo S., Mapelli P., Bezzi C., et al. Role of [(68)Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. (1619\u20137089 (Electronic))."},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40644-015-0038-0","article-title":"FDG-PET\/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy","volume":"15","author":"Beauregard","year":"2015","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.262250","article-title":"The added value of (18)F-FDG PET\/CT compared with (68)Ga-PSMA PET\/CT in patients with Castration-resistant prostate cancer","volume":"63","author":"Chen","year":"2022","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5489\/cuaj.11085","article-title":"Pre-treatment risk stratification of prostate cancer patients: a\u00a0critical review","volume":"6","author":"Rodrigues","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.acra.2024.06.034_bib26","unstructured":"Preisser F., Chun FKH, Pompe R.S., et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. (1873\u20137560 (Electronic))."},{"issue":"12","key":"10.1016\/j.acra.2024.06.034_bib27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2024.06.034_bib28","unstructured":"Watanabe\u00a0H.\u00a0,\u00a0Okada\u00a0M.\u00a0Fau\u00a0-\u00a0Kaji\u00a0Y.\u00a0,\u00a0Kaji\u00a0Y.\u00a0Fau\u00a0-\u00a0Satouchi\u00a0M.\u00a0, et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. (0385\u20130684 (Print))."},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","article-title":"Outcomes of active surveillance for men with intermediate-risk prostate cancer","volume":"29","author":"Cooperberg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO Guideline, part i: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"9-10","key":"10.1016\/j.acra.2024.06.034_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1159\/000516681","article-title":"The comparison of imaging and clinical methods to estimate prostate volume: a single-centre retrospective study","volume":"105","author":"Massanova","year":"2021","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.acra.2024.06.034_bib33","unstructured":"Epstein J.I., Egevad L Fau - Amin M.B., Amin Mb Fau - Delahunt B., Delahunt B Fau - Srigley J.R., Srigley Jr Fau - Humphrey P.A., Humphrey P.A.. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. (1532\u20130979 (Electronic))."},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmri.27596","article-title":"Metastatic diffusion volume based on apparent diffusion coefficient as a prognostic factor in castration-resistant prostate cancer","volume":"54","author":"Yamamoto","year":"2021","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"10.1016\/j.acra.2024.06.034_bib35","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/jmri.26178","article-title":"Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: preliminary findings","volume":"48","author":"Shiradkar","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.acra.2024.06.034_bib36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3389\/fonc.2020.00731","article-title":"Radiomics of multiparametric MRI to predict biochemical recurrence of localized prostate cancer after radiation therapy","volume":"10","author":"Zhong","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.acra.2024.06.034_bib37","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1002\/mp.15232","article-title":"Reliability of MRI radiomics features in MR-guided radiotherapy for prostate cancer: repeatability, reproducibility, and within-subject agreement","volume":"48","author":"Xue","year":"2021","journal-title":"Med Phys"},{"key":"10.1016\/j.acra.2024.06.034_bib38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3389\/fonc.2019.00807","article-title":"MRI-derived radiomics to guide post-operative management for high-risk prostate cancer","volume":"9","author":"Bourbonne","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bju.14794","volume":"124","author":"Scheltema","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.acra.2024.06.034_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.acra.2024.06.034_bib41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","article-title":"Role of FDG PET\/CT in management of patients with prostate cancer","volume":"54","author":"Sutherland","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"6","key":"10.1016\/j.acra.2024.06.034_bib42","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/jcm9061878","volume":"9","author":"Chong","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.acra.2024.06.034_bib43","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s00259-017-3779-0","article-title":"Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET\/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection","volume":"44","author":"Huang","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.acra.2024.06.034_bib44","unstructured":"Wang C., Zhao K., Hu S., et al. The PET-Derived Tumor-to-Liver Standard Uptake Ratio (SUV (TLR)) Is Superior to Tumor SUVmax in Predicting Tumor Response and Survival After Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer. (2234\u2013943X (Print))."},{"key":"10.1016\/j.acra.2024.06.034_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859323","article-title":"A machine learning model based on PET\/CT radiomics and clinical characteristics predicts tumor immune profiles in non-small cell lung cancer: a retrospective multicohort study","volume":"13","author":"Tong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.acra.2024.06.034_bib46","article-title":"Prediction of EGFR mutation status based on (18)F-FDG PET\/CT imaging using deep learning-based model in lung adenocarcinoma","volume":"11","author":"Yin","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.acra.2024.06.034_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","article-title":"Biological evolution of Castration-resistant prostate cancer","volume":"5","author":"Davies","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"24","key":"10.1016\/j.acra.2024.06.034_bib48","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"27","author":"Litwin","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.acra.2024.06.034_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004-2013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acra.2024.06.034_bib50","unstructured":"Carlin B.I., Andriole G.L.. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. (0008\u2013543X (Print))."}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633224004203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633224004203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T01:49:56Z","timestamp":1732672196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633224004203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1076633224004203"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2024.06.034","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Prognosis and Response to Androgen Deprivation Therapy in Intermediate to High-Risk Prostate Cancer Using 18F-FDG PET\/CT Radiomics","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2024.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}